DDX41 and Miyoshi myopathy: Furthermore, we assessed cross-neutralisation of the vaccine-induced Abs in MM patients and controls, i.e., capacity to inhibit Omicron BA.4/5 or XBB.1.5 RBD binding to the ACE-2 receptor.